Brain Cancer Press Releases

Designation for first-in-class OLIG2 inhibitor highlights the urgent need for new therapies in aggressive pediatric brain cancers and qualifies Curtana for a potential Priority Review Voucher upon FDA approval.

Official Foundation Launch to Elevate Awareness for Pediatric Brain Cancer

Curtana Pharmaceuticals Announces New Data Confirming CT-179 Effectively Crosses Blood-Brain Barrier and Synergizes with Radiation in Pediatric Brain Cancers

Preclinical Study Reveals that CT-179 Remodels the Tumor Microenvironment – Turning "Cold" Tumors "Hot" – and Significantly Enhancing the Efficacy of Immune Checkpoint Inhibitors

Curtana Pharmaceuticals, a biotechnology company focused on improving outcomes for brain cancer patients, is proud to announce the publication of two pioneering studies in Nature Communications.